OviflowOviflow
Blog
Get early access
Back to all posts
15 min read

IVF Monitoring During Stimulation: What to Expect

Dan

IVF monitoring during ovarian stimulation is one of the most important - and least explained - parts of the IVF process. It’s the series of blood tests and ultrasounds that track how your ovaries are responding to medication, and it directly informs every clinical decision: dose adjustments, when to trigger, and when to retrieve.

Yet many patients go through monitoring without fully understanding what’s being measured, why it matters, or what they should be looking for. This guide covers everything you need to know. We wrote it because we learned the hard way that monitoring isn’t just a routine formality - it’s where the critical decisions happen.

What Is IVF Monitoring?

IVF monitoring refers to the regular assessment of your ovarian response during the stimulation phase of an IVF cycle. It typically involves two components:

  1. Transvaginal ultrasound - to measure the number and size of developing follicles
  2. Blood tests - to measure hormone levels, primarily estradiol (E2), but also LH, progesterone, and sometimes others

Monitoring usually begins on day 2-3 of your cycle (baseline assessment) and continues every 2-3 days during stimulation, becoming more frequent (sometimes daily) as you approach the trigger shot. A typical stimulation phase involves 4-7 monitoring appointments over 8-14 days.

The purpose of monitoring is threefold:

  • Optimize egg yield: Ensure enough follicles are developing to justify proceeding to retrieval
  • Prevent complications: Identify signs of ovarian hyperstimulation syndrome (OHSS) early
  • Time the trigger precisely: Determine the optimal moment to administer the trigger shot for egg maturation

The Baseline Assessment

What happens

Before stimulation begins, most clinics perform a baseline assessment on cycle day 2 or 3. This includes:

  • Transvaginal ultrasound: The sonographer counts antral follicles (small, resting follicles) in each ovary. This is your antral follicle count (AFC), which helps predict how many eggs the stimulation might produce.
  • Blood tests: Typically FSH (follicle-stimulating hormone), LH (luteinizing hormone), estradiol, and sometimes AMH (anti-Mullerian hormone) if it hasn’t been tested recently.

What the numbers mean

Antral Follicle Count (AFC):

  • Below 5: Low ovarian reserve; a lower egg yield is expected
  • 5-15: Normal range
  • Above 15: Higher response expected; closer monitoring for OHSS risk
  • Above 25: High risk of OHSS; the protocol may be adjusted accordingly

FSH (cycle day 2-3):

  • Below 10 IU/L: Normal
  • 10-15 IU/L: Diminished ovarian reserve
  • Above 15 IU/L: Significantly diminished reserve; may indicate lower stimulation response

AMH (Anti-Mullerian Hormone):

  • Below 1.0 ng/mL: Low ovarian reserve
  • 1.0-3.5 ng/mL: Normal range
  • Above 3.5 ng/mL: High reserve; increased OHSS risk

These numbers help your RE determine the starting dose of gonadotropins and the overall stimulation strategy.

During Stimulation: What’s Being Tracked

Follicle size and number

During each monitoring ultrasound, the sonographer measures the diameter of each visible follicle in both ovaries. Follicles are the fluid-filled sacs in which eggs develop. Not every follicle will contain a mature egg, but follicle size is the best non-invasive indicator of egg maturity.

Follicle size milestones:

  • 5-9 mm: Small, pre-antral follicles; still developing
  • 10-13 mm: Growing follicles; responding to medication
  • 14-17 mm: Maturing follicles; approaching readiness
  • 18-22 mm: Mature follicles; likely to contain mature eggs at retrieval

The goal is to have a cohort of follicles reach 18-22 mm around the same time. Follicle synchrony - having most follicles at similar sizes - is important because the trigger shot matures all follicles simultaneously. If there’s too much size discrepancy, some eggs may be immature while others are over-mature.

According to Revelli et al. (2014), follicle size at the time of the trigger shot is one of the strongest predictors of mature oocyte yield. Their research found that follicles between 16-22 mm at trigger time had the highest probability of yielding a mature (MII) egg.

Estradiol (E2) levels

Estradiol is produced by growing follicles. As follicles develop, estradiol levels rise. Tracking estradiol helps confirm that follicles are hormonally active and producing eggs (not just fluid-filled cysts).

Estradiol benchmarks during stimulation:

  • Each mature follicle typically produces 200-400 pg/mL of estradiol
  • If you have 10 follicles, you’d expect E2 to be roughly 2,000-4,000 pg/mL near trigger
  • Rising E2 that plateaus or drops may indicate follicle regression
  • Very high E2 (above 3,000-5,000 pg/mL depending on the clinic) raises OHSS concerns

It’s important to note that estradiol levels should be interpreted in context - alongside follicle number and size, not in isolation. A high E2 with many large follicles is expected; a high E2 with few follicles may need investigation.

LH (Luteinizing Hormone)

LH is monitored to ensure you don’t surge prematurely. A natural LH surge triggers ovulation - if this happens before the planned retrieval, the eggs may be ovulated and lost. GnRH antagonist protocols specifically suppress LH to prevent premature surging.

LH monitoring:

  • Suppressed LH (below 1-2 IU/L): Expected on antagonist protocols
  • Rising LH (above 10 IU/L): May indicate a premature surge; may require earlier trigger or protocol adjustment
  • Some clinics don’t routinely monitor LH on antagonist protocols, assuming adequate suppression

Progesterone

Progesterone is sometimes measured during stimulation, particularly near the end. A premature rise in progesterone before the trigger shot may indicate that the endometrium is advancing ahead of the embryo, potentially reducing implantation chances for a fresh transfer.

Progesterone during stimulation:

  • Below 1.0 ng/mL: Normal during stimulation
  • 1.0-1.5 ng/mL: Borderline; may still be okay for fresh transfer
  • Above 1.5-2.0 ng/mL: The clinic may recommend a freeze-all cycle rather than fresh transfer

Research by Venetis et al. (2013) conducted a meta-analysis on premature progesterone elevation and found that elevated progesterone on the day of trigger was associated with lower pregnancy rates in fresh transfer cycles, but did not affect outcomes when embryos were frozen and transferred in a subsequent cycle.

Endometrial thickness

During monitoring, the ultrasound may also measure endometrial (uterine lining) thickness. While this is more relevant for the transfer phase, tracking it during stimulation provides early information.

Endometrial thickness benchmarks:

  • Below 7 mm: Thin lining; may affect implantation if doing a fresh transfer
  • 7-14 mm: Optimal range
  • Above 14 mm: Usually fine, though very thick linings warrant a pattern check (trilaminar pattern is ideal)

The Trigger Decision

When to trigger

The trigger shot (typically hCG, GnRH agonist, or a combination) induces the final maturation of eggs within the follicles. Timing is critical - too early and eggs won’t be mature; too late and ovulation may occur before retrieval.

The trigger decision is based on:

  • Lead follicle size: Most clinics trigger when 2-3 lead follicles reach 18-20 mm
  • Follicle cohort: The overall distribution of follicle sizes
  • Estradiol levels: Consistent with follicle development
  • LH levels: No evidence of premature surge
  • Progesterone levels: Not prematurely elevated
  • Duration of stimulation: Typically 8-14 days; prolonged stimulation may warrant earlier trigger

Types of trigger

  • hCG trigger (Ovitrelle, Pregnyl): The traditional trigger. Effective but carries higher OHSS risk.
  • GnRH agonist trigger (Lupron/Decapeptyl): Used in antagonist protocols. Significantly lower OHSS risk. May result in slightly lower oocyte yield.
  • Dual trigger (hCG + GnRH agonist): Combines both. Used in some protocols to optimize both maturation and safety.

The choice of trigger affects the timing of retrieval. hCG triggers typically have retrieval scheduled 36 hours later. GnRH agonist triggers may have slightly different timing.

Retrieval timing

After the trigger shot, egg retrieval is scheduled with precision - typically 34-36 hours later. This window is based on the biology of oocyte maturation: the trigger initiates the final steps of meiosis, and the egg needs to be retrieved before spontaneous ovulation occurs.

If retrieval is too early (less than 34 hours), eggs may be immature. If too late (more than 37-38 hours), some eggs may have already ovulated. This is why monitoring accuracy and trigger timing are so critical.

Dose Adjustments During Stimulation

Why doses change

Your starting dose of gonadotropins is based on your age, AMH, AFC, BMI, and previous cycle history (if any). But the actual response may differ from what was predicted. Monitoring allows your RE to adjust the dose in real time.

Common adjustments include:

  • Dose increase: If follicle growth is slower than expected, or if fewer follicles are developing. This is sometimes called a “poor response.”
  • Dose decrease: If too many follicles are developing or growing too fast, increasing OHSS risk. This is sometimes called a “hyper-response.”
  • Adding antagonist: In antagonist protocols, the GnRH antagonist (Cetrotide, Ganirelix) is typically added when lead follicles reach 12-14 mm to prevent premature LH surge.
  • Coasting: In rare cases of dangerously high OHSS risk, gonadotropins may be stopped entirely for 1-2 days while follicles continue growing. This is less common with modern protocols but is still used in some situations.

What you should know

Your RE makes these decisions based on monitoring data, but you should understand the rationale. At each monitoring appointment, ask:

  • “How many follicles are growing, and what sizes are they?”
  • “What are my estradiol levels, and are they where you’d expect?”
  • “Are we changing my medication dose? Why or why not?”
  • “When do you think we’ll trigger?”

You have every right to understand your own cycle data. You’re not being difficult by asking questions - you’re being an informed participant in your care.

Ovarian Hyperstimulation Syndrome (OHSS)

What is OHSS?

OHSS is a potentially serious complication of ovarian stimulation. It occurs when the ovaries over-respond to gonadotropins, becoming enlarged and leaking fluid into the abdomen. In severe cases, it can cause blood clots, kidney dysfunction, and even be life-threatening.

According to the RCOG (Royal College of Obstetricians and Gynaecologists, 2016), OHSS occurs in approximately 1-5% of IVF cycles in a mild form, with severe OHSS occurring in 0.1-2% of cycles.

Risk factors for OHSS

  • Young age (under 30)
  • Low BMI
  • Polycystic ovary syndrome (PCOS)
  • High AFC (above 20-25)
  • High AMH
  • Previous OHSS
  • High estradiol levels during stimulation
  • Use of hCG trigger
  • Pregnancy (hCG from pregnancy can worsen OHSS)

How monitoring prevents OHSS

Careful monitoring is the primary defense against severe OHSS. Warning signs during monitoring include:

  • Rapid development of many follicles (more than 20)
  • Rapidly rising estradiol (more than doubling every 2 days)
  • Very high estradiol levels (above 3,000-5,000 pg/mL, depending on clinic thresholds)
  • Large ovaries on ultrasound

If these signs appear, your RE may:

  • Reduce gonadotropin dose
  • Coast (stop stimulation temporarily)
  • Switch to a GnRH agonist trigger instead of hCG
  • Recommend freeze-all (no fresh transfer, as pregnancy worsens OHSS)
  • In extreme cases, cancel the cycle

The shift toward GnRH agonist triggers and freeze-all strategies has significantly reduced the incidence of severe OHSS in modern IVF practice. Humaidan et al. (2011) demonstrated that GnRH agonist triggering effectively prevents severe OHSS while maintaining oocyte yield.

OHSS symptoms to watch for

After retrieval, contact your clinic immediately if you experience:

  • Severe abdominal pain or bloating
  • Nausea and vomiting that won’t stop
  • Difficulty breathing or shortness of breath
  • Decreased urination (producing very little urine)
  • Rapid weight gain (more than 1 kg per day)
  • Dizziness or fainting

What Happens Between Appointments

Between monitoring visits, you continue your medication regimen as prescribed. This period can feel uncertain - you’re giving yourself injections and waiting for the next data point. Here’s what’s normal and what to watch for.

Normal during stimulation

  • Bloating and abdominal fullness (your ovaries are enlarging)
  • Mild pelvic discomfort or pressure
  • Mood swings and emotional volatility (from the hormones)
  • Fatigue
  • Mild breast tenderness
  • Frequent urination (enlarged ovaries pressing on the bladder)

When to call the clinic

  • Severe pain that isn’t relieved by over-the-counter pain medication
  • Fever above 38 degrees Celsius (100.4 degrees Fahrenheit)
  • Heavy vaginal bleeding (light spotting can be normal)
  • Signs of OHSS (see above)
  • Missed medication doses (call for guidance - don’t double up without instructions)

How to Be Your Own Advocate During Monitoring

Track your own data

Don’t rely solely on the clinic to track and communicate your numbers. After each monitoring appointment:

  • Ask for your follicle sizes (both ovaries)
  • Ask for your hormone levels (E2, LH, progesterone)
  • Write them down or enter them in a tracking app

Having your own record allows you to:

  • Notice trends that your busy clinic might not highlight
  • Ask informed questions at your next appointment
  • Have a reference if you change clinics
  • Compare across cycles if you do multiple rounds

This is one of the core problems we experienced with monitoring - when you don’t have your own data, you’re entirely dependent on the clinic’s interpretation and communication.

Ask questions at every appointment

You are not a passive recipient of care. At every monitoring visit:

  • “How does today compare to what you expected?”
  • “Are my follicles growing at a good rate?”
  • “Is my E2 where it should be for this many follicles?”
  • “When do you anticipate triggering?”
  • “Is there anything concerning?”

Understand when things aren’t going well

Sometimes monitoring reveals that a cycle isn’t going as planned. This might mean:

  • Poor response: Few follicles developing despite adequate medication. Your RE may increase the dose, extend stimulation, or in some cases recommend cancelling the cycle.
  • Uneven response: Large size discrepancy between follicles. This can result in a mix of mature and immature eggs at retrieval.
  • Hyper-response: Too many follicles, raising OHSS risk. Protocol adjustments are needed.

Understanding these scenarios in advance helps you participate in the decision-making rather than being caught off guard.

Monitoring in Special Situations

Natural and mini-IVF

In natural cycle IVF (no stimulation) or mini-IVF (minimal stimulation), monitoring is less intensive but still important. Fewer follicles mean less room for error in timing.

Frozen embryo transfer (FET) cycles

Monitoring for a FET cycle focuses on endometrial thickness and pattern rather than follicle development. Blood tests track estradiol and progesterone levels to time the transfer.

Egg freezing

Monitoring for egg freezing follows the same protocol as IVF stimulation - the goal is the same (mature follicles for retrieval), minus the fertilization and embryo culture steps.

Technology and the Future of Monitoring

Remote monitoring

Some clinics now offer remote monitoring components - at-home hormone testing kits and even portable ultrasound interpretation services. While these technologies are still evolving, they may reduce the burden of frequent clinic visits.

AI-assisted monitoring

Emerging research explores the use of artificial intelligence to predict ovarian response and optimize stimulation protocols. AI models can analyze patterns across thousands of cycles to suggest dose adjustments, though this technology is not yet standard practice.

Patient tracking tools

Apps and tools that allow patients to log their monitoring data, track trends, and share information with their partners can fill an important gap. When we built Oviflow, cycle tracking and monitoring data management was one of the first features we prioritized - precisely because of how much we struggled with it ourselves.

Key Takeaways

  • Monitoring consists of regular ultrasounds and blood tests during IVF stimulation
  • Follicle size, estradiol, LH, and progesterone are the key metrics being tracked
  • The trigger decision is based on follicle maturity, hormone levels, and overall response
  • OHSS is a real risk that careful monitoring helps prevent
  • You have the right to understand your monitoring data - ask for your numbers at every appointment
  • Track your own data independently so you can notice trends and ask informed questions
  • Dose adjustments during stimulation are normal and based on your individual response
  • Communication between you and your medical team during monitoring is critical

References

  1. Revelli A, et al. “Follicular size as a predictor of in vitro fertilization outcome.” Journal of Ultrasound in Medicine, 2014;33(4):611-618.
  2. Venetis CA, et al. “Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis.” Human Reproduction Update, 2013;19(5):433-457.
  3. Humaidan P, et al. “GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.” Human Reproduction, 2005;20(5):1213-1220.
  4. Royal College of Obstetricians and Gynaecologists. “Ovarian Hyperstimulation Syndrome, Management (Green-top Guideline No. 5).” RCOG, 2016.
  5. Bosch E, et al. “ESHRE guideline: ovarian stimulation for IVF/ICSI.” Human Reproduction Open, 2020;2020(2):hoaa009.
  6. La Marca A, Sunkara SK. “Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.” Human Reproduction Update, 2014;20(1):124-140.
  7. Nyboe Andersen A, et al. “Individualized versus conventional ovarian stimulation for in vitro fertilization.” Fertility and Sterility, 2017;107(6):1420-1430.
  8. Practice Committee of the American Society for Reproductive Medicine. “Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.” Fertility and Sterility, 2016;106(7):1634-1647.

This guide is part of our IVF knowledge series. We combine published medical evidence with our lived experience across 6 cycles, three clinics, and five years - not as medical advice, but as the thorough resource we wish we’d had when we started.

Dan, Co-founder of Oviflow